Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Author(s): Shuangbo Liu, Janine Eckstein, Anna Lam and Asim N. Cheema*

Volume 21, Issue 2, 2023

Published on: 27 February, 2023

Page: [111 - 119] Pages: 9

DOI: 10.2174/1570161121666230131120544

Price: $65

Abstract

Background: Evidence regarding using acetylsalicylic acid (aspirin) for the prevention of cardiovascular (CV) events in patients with diabetes mellitus (DM) is inconsistent. Therefore, we performed a meta-analysis.

Methods: A literature search was performed (January 1990 to February 2022) and publications meeting the inclusion criteria were reviewed, and a meta-analysis was performed using RevMan software. The primary outcome was a composite of CV death, non-fatal myocardial infarction (MI) and stroke. Secondary outcomes included all-cause mortality, individual components of the primary outcome and major bleeding.

Results: The study cohort comprised 33525 diabetic patients from 9 randomized controlled trials. The primary outcome was significantly lower for aspirin vs. placebo (7.9 vs. 8.6, RR (risk ratio) 0.92, 95% CI (confidence interval) 0.86-0.99). All-cause mortality (10 vs. 10.3%, RR 0.97, 95% CI 0.90-1.03), CV death (4.4 vs. 4.7%, RR 0.93, 95% CI 0.83-1.04), non-fatal MI (4.6 vs. 4.8% RR 0.97, 95% CI 0.83- 1.15) and stroke (3.2 vs. 3.5%, RR 0.89, 95% CI 0.75-1.06) were similar between the two treatment groups. Major bleeding was significantly higher for aspirin compared with placebo (3.4 vs. 2.8%, RR 1.18, 95% CI 1.01-1.39).

Conclusion: Aspirin use in patients with DM reduces the composite endpoint of CV death, non-fatal MI and stroke compared with a placebo. However, routine use of aspirin for primary prevention among diabetic patients cannot be advised due to the increased risk of major bleeding. These findings suggest careful risk assessment of individual patients.

« Previous Next »
Graphical Abstract

[1]
Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017; 376(15): 1407-18.
[http://dx.doi.org/10.1056/NEJMoa1608664] [PMID: 28402770]
[2]
Rawshani A, Rawshani A, Gudbjörnsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017; 377(3): 300-1.
[http://dx.doi.org/10.1056/NEJMc1706292] [PMID: 28723317]
[3]
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229-34.
[http://dx.doi.org/10.1056/NEJM199807233390404] [PMID: 9673301]
[4]
Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337(oct16 2): a1840.
[http://dx.doi.org/10.1136/bmj.a1840] [PMID: 18927173]
[5]
Kassoff A, Buzney SM, McMeel JW, et al. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA 1992; 268(10): 1292-300.
[http://dx.doi.org/10.1001/jama.1992.03490100090033] [PMID: 1507375]
[6]
Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26(12): 3264-72.
[http://dx.doi.org/10.2337/diacare.26.12.3264] [PMID: 14633812]
[7]
Saito Y, Okada S, Ogawa H, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes: 10-year follow-up of a randomized controlled trial. Circulation 2017; 135(7): 659-70.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.025760] [PMID: 27881565]
[8]
Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379(16): 1529-39.
[http://dx.doi.org/10.1056/NEJMoa1804988] [PMID: 30146931]
[9]
Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: Updated meta-analysis of randomized controlled trials. Diabet Med 2017; 34(3): 316-27.
[http://dx.doi.org/10.1111/dme.13133] [PMID: 27086572]
[10]
Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: Updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol 2019; 18(1): 70.
[http://dx.doi.org/10.1186/s12933-019-0875-4] [PMID: 31159806]
[11]
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-96.
[http://dx.doi.org/10.1016/S0140-6736(04)16895-5] [PMID: 15325833]
[12]
Khan SU, Ul Abideen Asad Z, Khan MU, et al. Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. Eur J Prev Cardiol 2020; 27(19): 2034-41.
[http://dx.doi.org/10.1177/2047487319825510] [PMID: 30700151]
[13]
Kokoska LA, Wilhelm SM, Garwood CL, Berlie HD. Aspirin for primary prevention of cardiovascular disease in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 2016; 120: 31-9.
[http://dx.doi.org/10.1016/j.diabres.2016.07.012] [PMID: 27500549]
[14]
Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13): 1293-304.
[http://dx.doi.org/10.1056/NEJMoa050613] [PMID: 15753114]
[15]
Higgins JPT, Lasserson T, Chandler J, Tovey D, Churchill R. Methodological expectations of Cochrane intervention reviews (MECIR). London: Cochrane 2016.
[16]
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4(1): 1.
[http://dx.doi.org/10.1186/2046-4053-4-1] [PMID: 25554246]
[17]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[18]
CADTH. Grey matters: A practical tool for searching health-related grey literature. Ottawa: 2018. Available from: https://www.cadth.ca/resources/finding-evidence
[19]
Fortuni F, Crimi G, Gritti V, Mirizzi AM, Leonardi S, Ferrari GMD. Primum non nocere : An updated meta-analysis on aspirin use in primary prevention of cardiovascular disease in patients with diabetes. Eur J Prev Cardiol 2019; 26(15): 1677-9.
[http://dx.doi.org/10.1177/2047487319826439] [PMID: 30744399]
[20]
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343(oct18 2): d5928.
[http://dx.doi.org/10.1136/bmj.d5928] [PMID: 22008217]
[21]
Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial. JAMA 2014; 312(23): 2510-20.
[http://dx.doi.org/10.1001/jama.2014.15690] [PMID: 25401325]
[22]
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351(9118): 1755-62.
[http://dx.doi.org/10.1016/S0140-6736(98)04311-6] [PMID: 9635947]
[23]
McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018; 379(16): 1519-28.
[http://dx.doi.org/10.1056/NEJMoa1803955] [PMID: 30221595]
[24]
Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007; 115(10): 1285-95.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.652859] [PMID: 17353456]
[25]
Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016; 118(4): 620-36.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.306301] [PMID: 26892962]
[26]
Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms. Circulation 2006; 113(15): 1888-904.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.563213] [PMID: 16618833]
[27]
Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Review article: Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010; 7(4): 251-9.
[http://dx.doi.org/10.1177/1479164110383994] [PMID: 20921090]
[28]
Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2(8): 1282-91.
[http://dx.doi.org/10.1111/j.1538-7836.2004.00836.x] [PMID: 15304032]
[29]
Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 2009; 32(4): 525-7.
[http://dx.doi.org/10.2337/dc08-1865] [PMID: 19336636]
[30]
Vaduganathan M, Alviar CL, Arikan ME, et al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J 2008; 156(5): e1-7.
[http://dx.doi.org/10.1016/j.ahj.2008.08.002]
[31]
Galli M, Andreotti F, D’Amario D, et al. Aspirin in primary prevention of cardiovascular disease in the elderly. Eur Heart J Cardiovasc Pharmacother 2020; 6(5): 326-7.
[http://dx.doi.org/10.1093/ehjcvp/pvz046] [PMID: 31504373]
[32]
American Diabetes Association. A. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2021. Diabetes Care 2021; 44 (Suppl. 1): S125-50.
[http://dx.doi.org/10.2337/dc21-S010] [PMID: 33298421]
[33]
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255-323.
[http://dx.doi.org/10.1093/eurheartj/ehz486] [PMID: 31497854]
[34]
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol 2019; 74(10): 1376-414.
[http://dx.doi.org/10.1016/j.jacc.2019.03.009] [PMID: 30894319]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy